Platelet GPIIb-IIIa blockers

Lancet

Volumn 353, Issue 9148, 1999, Pages 227-231

  Topol, Eric J ^a   Byzova, Tatiana V ^a   Plow, Edward F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN; TIROFIBAN;

ARTICLE; CLINICAL TRIAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0033573790     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)11086-3     Document Type: Review

References (48)

1. Anon. A new blood corpuscle. Lancet 1882; i: 111-12.
2. Glanzmann E Hereditare haemorrhagische Thrombasthenie: ein beitrag zur pathologie der blutplattchen. Jahrb Kinderheilk. 88:1918;113-114.
3. Nurden AT, Caen JP An abnormal glycoprotein pattern in three cases in Glanzmann's thromboasthenia. Br J Haematol. 28:1974;253-260.
4. Hynes RO Integrins: a family of cell surface receptors. Cell. 48:1987;549-550.
5. Phillips DR, Charo IF, Parise LV, Fitzgerald LA The platelet membrane glycoprotein IIb-IIIa complex. Blood. 71:1988;831-843.
6. Bennett JS Structural biology of glycoprotein IIb-IIIa. Trends Cardiovasc Med. 6:1996;31-36.
7. Calvete JJ Clues for understanding the structure and function of a prototypic human integrin. Thromb Haemost. 72:1994;1-15.
8. Hynes RO Integrins: versatility, modulation, and signalling in cell adhesion. Cell. 69:1992;11-25.
9. Weiss EJ, Bray PF, Tayback Met al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 334:1996;1090-1099.
10. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 350:1997;1217-1219.
11. Duperray A, Troesch A, Berthier R, Chagnon E, Frachet P, Uzan G, Marguerie G Biosynthesis and assembly of platelet GPIIb-IIIa in human megakaryocytes. Blood. 74:1989;1603-1611.
12. Plow EF, D'Souza SE, Ginsberg MH Ligand binding to GPIIb-IIIa: a status report. Sem Thromb Haemost. 18:1992;324-332.
13. vß3 in vascular biology. Thromb Haemost. 80:1998;726-734.
14. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 88:1996;9907-9914.
15. Haas TA, Plow EF Integrin-ligand interactions. Curr Opin Cell Biol. 6:1994;656-662.
16. 3 binds prothrombin and influences its activation. J Biol Chem. 272:1997;27183-27188.
17. Goto S, Ikeda Y, Saldivar E, Ruggeri Z Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest. 101:1998;479-486.
18. Hughes PE, Pfaff M Integrin affinity modulation. Trends Cell Biol. 8:1998;359-364.
19. Shattil SJ, Ginsberg MH Integrin signaling in vascular biology. J Clin Invest. 100:1997;S91-95.
20. Humphries MJ Integrin activation. Curr Opin Cell Biol. 8:1996;632-640.
21. Schwartz MA, Schaller MD, Ginsberg MH Integrins. Annu Rev Cell Biol. 11:1995;549-599.
22. Sabovic M, Lijnen HR, Keber D, Collen D Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost. 62:1989;1083-1087.
23. Frelinger AL III, Lam SC-T, Plow EF, Smith MA, Loftus JC, Ginsberg MH Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem. 263:1988;12397-12402.
24. Lefkovits J, Plow EF, Topol EJ Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559.
25. Jordan RE, Mascelli MA, Nakada MT, Weisman HF. Pharmacology and clinical development of abciximab (c7E3 Fab, ReoPro): In: Gasahara AA, Losaelzo J, eds. New therapeutic agents in thrombosis and thrombolysis. New York: Marcel Dekker, 1997: 291-313.
26. Phillips DR, Scarborough RM Clinical pharmacology of eptifibatide. Am J Cardiol. 80:1997;11B-20B.
27. Farrell DH, Thiagarajan P, Chung DW, Davie EW Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci USA. 89:1992;10729-10732.
28. Ruoslahti E RGD and other recognition sequences for integrins. Annu Rev Cell Biol. 12:1996;697-715.
29. Egbertson MS, Chang CT-C, Duggan MEet al. Non-peptide fibrinogen receptor antagonists I. I. J Med Chem. 37:1994;2537-2551.
30. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
31. The IMPACT II Investigators. Effects of competitive platelet glycoprotein IIb/IIIa inhibition with integrelin in reducing complications of percutaneous coronary intervention. Lancet 1997; 349: 1422-28.
32. EPILOG Investigators. Effect of the platelet glycoprotein II/IIIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
33. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-35.
34. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina. N Engl J Med 1998; 338: 1498-505.
35. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
36. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
37. PARAGON Investigators. A randomized trial of potent platelet IIb/IIIa antagonism, heparin or both in patients with unstable angina. Circulation 1996; 94: I-553 (abstr).
38. The PURSUIT Investigators. Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. N Engl J Med 1998; 339: 436-43.
39. The EPISTENT Investigators. Randomised controlled trial to assess safety of coronary stenting with use of abciximab. Lancet 1998; 352: 85-90.
40. 3 blockade with percutaneous coronary intervention. JAMA. 278:1997;479-484.
41. Lincoff AM, Tcheng JE, Califf RM, et al. the SPISTENT trial at 6 months: relative and combined effects of abciximab and stenting on reduction of acute ischemic events and laterevascularization. Circulation 1998;, suppl 98: I-767 (abstr).
42. Topol EJ. Adjunctive therapy with coronary stenting: EPISTENT-1-year results. Presented at American Heart Association meeting (Dallas, Texas, Nov 7, 1998).
43. Brener SJ, Barr LA, Burchenal JEBet al. A randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 98:1998;734-741.
44. Harrington RA, Graffagnino C, Armstrong PW, et al. Dose-finding and tolerability of a new oral platelet glycoprotein IIb/IIIa inhibitor, SB 214857, in patients with coronary artery and cerebrovascular disease. Circulation 1998; 98 (suppl I): I-251 (abstr).
45. Topol EJ Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation. 97:1998;211-218.
46. Topol EJ, Lincoff AM, Sapp S Coronary stenting and use of abciximab. Lancet. 352:1998;1311-1312.
47. Tcheng JE, Kereiakes DJ, Branden GA, et al. Safety of abciximab retreatment: final clinical report of the Reopro Readministration Registry (R3). Circulation 1998; 98 (suppl I): I-17.
48. 3) inhibitors. Blood. 92:1998;3240-3249.